Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Synthetica Bio lates to tap generative AI to spur drug discovery innovation

By Brian Buntz | July 24, 2023

Synthetica BioInterest in generative AI has skyrocketed in 2023. While the generative AI market is already substantial, worth $10 billion in 2022 according to Grand View Research, it is set to balloon by a compound annual growth rate (CAGR) of 35.6% from 2023 to 2030.  It’s no wonder that a slew of companies — including Exscientia, Insilico Medicine, Atomwise and BenevolentAI — are eager to tap the technology to expedite drug discovery.

Enter Synthetica Bio

The latest entrant in the generative AI scene is Laguna Beach, California-based Synthetica Bio. The startup aims to explore generative AI and large language models (LLMs) to enable real-time data processing. The company, founded by Simon Arkell and Alex Dickinson, entrepreneurs with a successful track record in companies like the predictive analytics firm Predixion, digital pathology startup Deep Lens, biotech Helixis and the molecular diagnostics firm Chromacode, has formed strategic partnerships to propel its platform development.

Strategic partnerships are at the heart of Synthetica Bio’s approach

Simon Arkell

Simon Arkell

Out of the gate, the company has a partnership with Microsoft that provides it with access to their cloud service, Azure, and a shared history of successful collaboration in the healthcare and life sciences sector. “We’re very early stage yet but we’ve committed to Microsoft and Azure within their program,” said Simon Arkell, CEO of Synthetica Bio.

Additionally, Synthetica Bio has formed a partnership with one of the largest healthcare data providers in the industry, allowing them to use de-identified data on more than 200 million American patients to fine-tune their models.

Synthetica Bio also differentiates itself from competitors with its trove of data from more than 220 million Americans. “But the secret sauce is that this is in a secure cloud,” Arkell adds, emphasizing the importance of data privacy and security in their operations.

User-centricity also key

Created to serve multiple departments within a pharmaceutical company, including marketing, drug discovery, and clinical trials, the platform’s user-centric design empowers analysts, scientists and other users to pose data-driven questions directly, sans a dedicated data science team. “We’re building an environment where the analyst, the PhD, the clin ops staffer, the scientist can query the data without going through a data science team,” Arkell elaborated.

In addition to its multi-disciplinary utility, Synthetica Bio prioritizes user-friendliness. “We’re operating at the abstraction level above the data, where a drag-and-drop UI helps user personas construct their own copilots,” Arkell noted.

The promise of generative AI in an ever-evolving landscape

Arkell stressed the importance of keeping pace in a swiftly progressing field. “The beauty of a modular, orchestration platform leveraging many large language models and data…means the platform will stay cutting-edge, continuously gaining intelligence and never becoming obsolete.”

Flexibility is also an attribute of Synthetica Bio’s platform. “Users can run it either on our secure cloud, where they can apply their data for training and tuning, or host the software on their own cloud instance,” Arkell explained further, spotlighting the security and adaptability of their offering.

Arkell believes embracing generative AI is vital for companies to stay relevant. “Many companies have initiatives underway and budgets,” he said. “The very largest firms we’ve engaged already have data science teams and need to adopt generative AI to remain competitive.”

Synthetica Bio is targeting an underserved market

When asked about conversations so far with biopharma companies, Arkell noted significant interest in the industry for generative AI, with many firms actively experimenting and building out teams. He noted that fully capitalizing on the technology requires major investments that may be out of reach for smaller players.

Arkell explained that Synthetica Bio is devoting itself full-time to building an enterprise-level AI platform. He believes mid-sized biopharmas without large data science teams represent a prime target market, as they lack the internal resources to harness generative AI themselves but recognize the need for tailored AI technologies.

Looking ahead, Arkell sees Synthetica Bio’s platform as a tool for those mid-size companies without extensive data science capabilities. “We’re encountering high demand from organizations with extensive data, needing quick insights from their resources,” he noted.


Filed Under: Data science, machine learning and AI
Tagged With: AI in Pharma, Cloud Technology, data science, drug discovery, generative AI, Healthcare Data, strategic partnerships
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Abstract neural network
Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials
Xaira and Verily co-founder ponders low-hanging fruit and blue-sky potential in FDA’s genAI rollout
Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE